Smoking Increases Relapse Rate in RRMS Patients on Tysabri, Study Suggests
August 7, 2018 Smoking increases the relapse rate in patients with relapsing-remitting multiple sclerosis being treated with Tysabri , an…
Long-term DMT Use Seen to Lower Likelihood of RRMS Progressing to SPMS in Study
AUGUST 15, 2018 – BY PATRICIA INACIO, PHD Long-term treatment with disease-modifying therapies (DMTs) appears to lessen the risk of disease worsening in relapsing-remitting…
Stuart Schlossman
TG Therapeutics Reaches Target Enrollment in Phase 3 Trials to Test Ublituximab in Relapsing MS
TG Therapeutics announced it has reached target enrollment in the ULTIMATE I and II Phase 3 clinical trials assessing the…
Stuart Schlossman
Hair Loss Seen in RRMS Patients Using Aubagio Often Temporary and Mild, Study Says
Hair Loss Seen in RRMS Patients Using Aubagio Often Temporary and Mild, Study Says Hair thinning in relapsing-remitting multiple sclerosis…
Stuart Schlossman
More on Gilenya® as the first disease-modifying therapy for pediatric relapsing multiple sclerosis
In May 2018, Novartis announced FDA approval of Gilenya® as the first disease-modifying therapy for the treatment of children and adolescents 10…
Stuart Schlossman
Shorter Washout Period Lessens Relapse Risk When Switching from Tysabri to Gilenya in RRMS
Shortening the washout period to four weeks when switching from Biogen’s Tysabri (natalizumab) to Novartis’ Gilenya (fingolimod) is safe and reduces the chances of experiencing a…
Stuart Schlossman
Are Off-Label Drugs Safe for Treating MS?
A webMd article: When your doctor suggests a drug to treat your multiple sclerosis (MS), your first move may be to search…
Stuart Schlossman
Evaluation of no evidence of progression or active disease (nepad) in patients with primary progressive multiple sclerosis in the oratorio trial
ABSTRACTS: Objectives To assess the effect of ocrelizumab from baseline to Week 120 on the proportion of patients with no…
Stuart Schlossman
First clinical trial to recognize the needs of severely disabled MS patients
Jun 13, 2018 – UK NEWS A new clinical trial testing a disease-modifying drug for multiple…
Stuart Schlossman
Comparisons of therapies in different scenarios help complete the puzzle
Escalation of therapy is the most widely used strategy for managing active relapsing-remitting multiple sclerosis. The difficulty in tailoring the…
Stuart Schlossman
